<p>CSPC Pharmaceutical Group Limited announced that it has received approval from the National Medical Products Administration of China to conduct clinical trials for its SYS6055 Injection. The product is intended for the treatment of relapsed or refractory aggressive B-cell lymphoma and may also have potential applications for other CD19-positive B-cell malignancies and autoimmune diseases. SYS6055 is noted as the first in vivo CAR-T product approved for clinical trials in China, designed to generate CAR-T cells directly in vivo using lentiviral vectors. Preclinical studies have shown promising results in tumor inhibition and safety, indicating potential advantages in cost, accessibility, and treatment immediacy compared to traditional CAR-T therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260129-12005082), on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

588130

159849

562050

516930

300765

159837

512010

512290

159992

516500

Reuters

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

CSPC Innovation

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

CSPC Pharmaceutical Group Wins China Approval for SYS6055 Injection Clinical Trials